Ethinamate

Regular use leads to drug tolerance, and it is usually not effective for more than 7 days. Prolonged use can lead to dependence.^{[citation needed]}

Ethinamate

Clinical data
AHFS/Drugs.com	Micromedex Detailed Consumer Information
Routes of administration	Oral
ATC code	none
Legal status
Legal status	BR: Class B1 (Psychoactive drugs) CA: Schedule IV DE: Anlage II (Authorized trade only, not prescriptible) UK: Class C US: Schedule IV In general: ℞ (Prescription only)
Identifiers
IUPAC name (1-ethynylcyclohexyl)carbamate
CAS Number	126-52-3 Y
PubChem CID	3284
IUPHAR/BPS	7325
DrugBank	DB01031 Y
ChemSpider	3169 Y
UNII	IAN371PP48
KEGG	D00703 Y
ChEBI	CHEBI:4884 Y
ChEMBL	ChEMBL1576 Y
CompTox Dashboard (EPA)	DTXSID7023013
ECHA InfoCard	100.004.355
Chemical and physical data
Formula	C9H13NO2
Molar mass	167.208 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C(OC1(C#C)CCCCC1)N
InChI InChI=1S/C9H13NO2/c1-2-9(12-8(10)11)6-4-3-5-7-9/h1H,3-7H2,(H2,10,11) Y Key:GXRZIMHKGDIBEW-UHFFFAOYSA-N Y
(verify)

Ethinamate has been replaced by other medicines (particularly benzodiazepines), and it is not available in the Netherlands, the United States or Canada.^{[citation needed]}

It is a schedule IV substance in the United States.

Ethinamate (1-ethynylcyclohexanone carbamate) is synthesized by combining acetylene with cyclohexanone to make 1-ethynylcyclohexanol, and then transforming this into a carbamate by the subsequent reaction with phosgene, and later with ammonia. Some lithium metal or similar is used to make the acetylene react with the cyclohexanone in the first step.